2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States BG00012 (DMF) - Relapsing Forms of Multiple Sclerosis | Phase 4 | Completed | Biogen | 237 | 2013-05-01 | 2017-03-21 |
| A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod, Standard MS DMTs - Relapsing Forms of Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 1053 | 2010-08-01 | 2014-02-10 |
Dimethyl Fumarate (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1) · Interferon beta-1a (1) · Interferon beta-1b (1)
Biogen (1) · Novartis Pharmaceuticals (1)
United States (2) · Canada (1) · Puerto Rico (1)